<DOC>
	<DOCNO>NCT02492412</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety HE10 eye drop patient moderate severe dry eye syndrome .</brief_summary>
	<brief_title>Efficacy Safety HE10 Dry Eye Syndrome</brief_title>
	<detailed_description>This study compare efficacy safety HE10 Restasis patient moderate severe dry eye syndrome multi-center , double-blind , randomize , active comparator-controlled , parallel design , non-inferiority Phase III clinical trial .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Corneal stain score â‰¥2 ( Oxford grade ) Schirmer test score ( without anesthesia ) &lt; 10 mm/5 min either eye Tear breakup time 10 second less Screening eye , correct visual acuity 0.2 Current recent patient use dry eye syndrome medication ( topical systemic ) may affect status The patient systemic ocular disorder affect test result Being treat systemic steroid History eyeball surgical operation within 3 month screen visit Wearing contact lenses within 2 week screen visit Be use use punctual plug within 1 month screen vist Use cyclosporine eye drop within 3 week Pregnancy Breastfeeding Intraocular pressure &gt; 25 mmHg Abnormal eyelid function : Disorders eyelids eyelash</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>